Introduction
Human telomerase, a ribonucleoprotein enzyme, extends chromosome ends with (TTAGGG) n telomeric sequences and thus has a key role in maintaining telomere length and in cellular replicative life span. [1] [2] [3] This ribonucleoprotein, usually absent or expressed at a low level in most normal somatic cells, is highly active in cancer cells, strongly indicating its key role in cell immortalization and carcinogenesis. 4 Owing to its differential expression pattern in normal and tumor cells, telomerase has been proposed as a promising target for anticancer therapies. 5 The human telomerase is composed of at least two components, a template RNA component (hTR) and a catalytic subunit, telomerase reverse transcriptase (hTERT). 6, 7 As hTERT expression is one determinant for the control of telomerase activity, elucidation of the regulatory mechanisms of hTERT expression will contribute to a better understanding of telomerase activity control at the molecular level.
The hTERT promoter contains two E-box regions, which could be bound by basic helix-loop-helix transcription factors such as c-Myc, Max or Mad-1, [8] [9] [10] and five GC boxes, which work as binding sites for Sp-1 transcriptional factor ( Figure 5 , top). c-Myc/Max, as well as Sp1, positively regulates hTERT transcription, whereas Mad-1/Max has a negative regulatory effect. [11] [12] [13] [14] [15] In addition, a number of protein factors have been shown to negatively regulate hTERT; among them are the CCCTC-binding factor (CTCF), 16, 17 the transcription activator protein 1 (AP-1), 18 the tumor suppressor, Menin, 19 the myeloid cell-specific zincfinger protein 2 (MZF-2), 20 and the Wilms' tumor protein (WT1). 21 Epigenetic control and overall chromatin structure have recently been shown to be also important parameters in hTERT gene regulation. hTERT gene was reported to be embedded in a condensed chromatin domain contributing to its silencing. [22] [23] [24] The high GC content within the proximal core promoter of hTERT suggests that DNA methylation might be involved in controlling hTERT expression. [25] [26] [27] [28] [29] [30] A careful analysis of hTERT methylation patterns has recently shown that a short region of the CpG island remains unmethylated or slightly methylated despite the neighboring regions being highly methylated. 31 This unmethylated region spreads from nucleotide (nt) positions À279 to þ 5 in the hTERT core promoter and creates a favorable context for transcription. In addition to DNA methylation, histone modifications have a critical role in the modulation of hTERT expression, 32 probably through affecting the accessibility of the regulatory sequences to the transcriptional factors.
Previous studies, including our own, showed that hTERT repression is associated with cell differentiation. [33] [34] [35] This repression was explained by chromatin modifications such as progressive hypoacetylation, accumulation of methylated cytosines in the hTERT promoter and switch from Myc/Max to Mad1/ Max binding. As almost all studies so far have been performed on maturation-sensitive cells, the mechanisms involved in hTERT repression independent of differentiation remain unclear.
Using a model of acute promyelocytic leukemia (APL) cells (NB4-LR1) resistant to maturation induced by retinoids, including all-trans retinoic acid (ATRA), 36 we identified a new pathway of hTERT repression. 33 This pathway led to downregulation of telomerase activity, telomere shortening, growth arrest and cell death. Importantly, we reported the isolation of a variant of NB4-R1 cells (NB4-R1 SFD ), which bypasses this death step, because of a reactivated telomerase, despite the continuous presence of ATRA. 37 It is noteworthy that the reactivation of telomerase after an initial step of downregulation resembles what is observed during tumorigenesis when telomerase is reactivated; therefore, this cell line could serve as a unique cell model to study the molecular events occurring during the oncogenic reactivation of telomerase.
In this study, we used this pair of NB4-R1 cell variants to address the regulatory mechanisms of hTERT repression induced by ATRA long-term treatment independently of differentiation and investigate the molecular mechanisms of hTERT reactivation. We show that both modulation of expression and function of transcription factors targeting the proximal region of the hTERT promoter, as well as epigenetic modifications targeting the distal promoter region, could account for hTERT reactivation and resistance to ATRA-induced hTERT downregulation.
Materials and methods

Chemicals and cell culture
ATRA, benzoyloxycarbonyl-Leu-Leu-Leu-aldehyde (MG-132) and 5-aza-2 0 -deoxycytidine (5-azadC) were from Sigma (St Louis, MO, USA). The maturation-resistant human APL cell lines, NB4-LR1 and the selected subline NB4-LR1 SFD , were cultured as previously described. [37] [38] [39] [40] All cells were incubated at 37 1C at 5% CO 2 atmosphere (Binder Incubators, Nanterre, France). For treatment, cells were seeded at a density of 1-2 Â 10 5 cells/ml in medium supplemented with ATRA (1 mM). Every 2 or 3 days, cell density was determined using Coulter counting, and when it reached 6-7 10 5 cells/ml, cells were re-seeded to a new flask in medium supplemented or not with ATRA (1 mM).
Telomerase activity assay
Telomerase activity was measured using the telomerase PCR enzyme-linked immunosorbent assay kit (Roche Diagnostics, Meylan, France) according to the manufacturer's instructions. Telomerase activity was expressed as a percentage of that detected in untreated cells.
Analysis of hTERT expression by real-time PCR
Total RNA was isolated using TRIzol reagent (Invitrogen, Cergy Pontoise, France) as described by the manufacturer and subjected to reverse transcription (RT) reaction using Transcriptor First Strand cDNA Synthesis Kit (Roche Diagnostics). Full-length hTERT mRNA expression was quantified by fluorescence real-time reverse transcriptase PCR using the LightCycler technology and the LightCycler TeloTAGGG hTERT Kit from Roche Diagnostics according to the manufacturer's instructions. hTERT level was normalized to the expression of the housekeeping gene porphobilinogen deaminase.
Immunoblots
Total cellular proteins were extracted with SDS lysis buffer and 10 mg of proteins were separated by SDS-polyacrylamide gel electrophoresis and transferred onto a nitrocellulose membrane. The membranes were then probed with the appropriate dilution of the following primary antibody: anti-actin (Sigma), anti-c-myc (BD Biosciences Pharmingen, Le-Pont-de-Claix, France), antiMad-1 (Santa Cruz, sc-222, Tebu France, Le Perray en Yvelines, France), anti-Sp1 (07-645, Upstate, Millipore, Molsheim, France), anti-CTCF (07-729, Millipore) and anti-WT1 (Santa Cruz, sc-192). After washing, blots were then incubated with the appropriate horseradish peroxidase-conjugated secondary antibody and then developed by enhanced chemiluminescence (Perkin Elmer Life Sciences, Courtaboeuf, France).
DNA isolation and bisulfite treatment
Genomic DNA from ATRA-treated and nontreated cells was isolated as previously described. 41 Bisulfite modification and DNA purification were carried out using EZ DNA methylation kit (Zymo Research, Proteigen, Saint-Marcel, France) following the manufacturer's instructions.
Bisulfite sequencing
Bisulfite-modified genomic DNA was analyzed using a set of primers spanning a region from À650 to þ 150 from the transcription start site of hTERT as previously described. 31 The primer sequences and conditions are shown in Supplementary  Table S1 . Their locations are shown in Figure 5 (top). All PCRs were carried out using hot-start Taq DNA polymerase (Clontech, Ozyme, Saint-Quentin en Yvelines, France). PCR products were run on 1.5% agarose gels and bands were excised using QIAquick Gel Extraction Kit (Qiagen, Courtaboeuf, France) following the manufacturer's instructions. Purified bands were cloned into the PGEM-T Easy vector (Promega, Charbonnières-les-Bains, France) following the manufacturer's instructions. Colonies were selected and grown overnight in Luria-Bertani medium containing ampicillin (100 mg/ml). Plasmid DNA was isolated using Nucleospin plasmid kit (Macherey-Nagel, Hoerdt, France) following the manufacturer's instructions. In each experiment, about ten plasmid subclones were used and sequenced (MWG biotech, Ebersberg, Germany) using the pGEM-1 Easy vector primers T7 and Sp6. The results of methylation analyses were expressed as total methylation index calculated for each cell line and clone by dividing the number of methylated CpGs by the total CpGs analyzed and expressed as percent methylation. The number of methylated CpGs at a specific site was divided by the number of clones analyzed to yield a percentage of methylation for each site.
ChIP assays and PCR amplification
Chromatin immunoprecipation (ChIP) assays for acetylation of histone and RNA Pol II binding to hTERT promoter were performed using the ChIP Assay kit according to the manufacturer's instruction (Millipore, Upstate). Briefly, cells were crosslinked with 1% formaldehyde and sonicated to obtain DNA fragments of 500-800 bp in length. An aliquot of the crosslinked chromatin was saved as input fraction after preclearing with protein A agarose. A total of 4 mg of an antibody (Ab) to RNA Pol II antibody (Santa Cruz, sc-899) or to acetylated H3 or H4 (06-599 and 06-866; Upstate, Millipore) was added to the chromatin sample for immunoprecipitation (IP), which was performed by adding salmon sperm DNA-protein A Agarose (50% slurry). An equal amount of TE (10 mM Tris-HCl, pH 8.0, 1 mM EDTA) was added to the corresponding chromatin sample being used as a negative control (No Ab). IP, input and No Ab fractions were then recovered, uncrosslinked and purified before being analyzed by PCR with appropriated primer pairs. Primer sequences are shown in Supplementary Table S1 . For real-time PCR, a SYBR green reagents kit was used (Roche Diagnostics). Relative abundance of each amplified fragment was compared hTERT regulation by retinoids in maturation-resistant APL cells A Azouz et al after normalization of the quantity of each fragment ChIP sample with the quantity of the total input DNA sample. ChIP assays for binding of transcription factors were carried out with some modifications to the above protocol. After crosslinking, the nuclei were isolated and resuspended in ChIP lysis buffer (0.1% SDS, 0.1% Na-deoxycholate, 1% Triton X-100, 1 mM EDTA, 140 mM NaCl, 10 mM Tris pH 8 and protease inhibitor cocktail) and sonicated. Immunoprecipitation was then performed as above using 4 mg of an antibody to c-Myc (Santa Cruz, sc-764), Mad1 (Santa Cruz, sc-222), Sp1 (07-645, Upstate, Millipore), CTCF (07-729, Upstate, Millipore) or WT1 (Santa Cruz, sc-192).
Results
Long-term downregulation of hTERT by ATRA is defective in NB4-LR1 SFD cells
As previously reported, 33,37 telomerase can be repressed by ATRA independently of terminal maturation during long-term treatment of the NB4-LR1 maturation-resistant APL cell line ( Figure 1 ). In contrast, despite the continuous presence of ATRA, a high level of hTERT mRNA (40-50% of control expression) and high telomerase expression was observed in NB4-LR1 SFD cells even after 30 days of exposure to ATRA. We therefore used this pair of NB4-LR1 cell variants to address the regulatory mechanisms of hTERT repression induced by ATRA long-term treatment independently of differentiation.
Differential modulation of RNA Pol II association at hTERT promoter by ATRA To quantify the actual transcriptional rate of hTERT on ATRA long-term treatments, RNA Pol II occupancy at the promoter of hTERT gene was analyzed using RNA-Pol-ChIP assay. 42 Given that association of RNA Pol II with gene-coding regions has been previously shown to coincide with active gene transcription and that analysis at coding region avoids immunoselection of nonelongating paused RNA Pol II at the promoter of target genes, RNA Pol II binding at exon 2 was also investigated. As a specific positive control, we performed PCR analyses using primers specific to a region encompassing retinoic acid receptor (RAR)b2 response element (RARE). Indeed, RARb2 gene, a ATRA-inducible gene, is under the control of a promoter that contains a canonical RARE. 43 Figure 2 shows a marked decrease in the association of RNA Pol II with hTERT promoter and exon 2 in NB4-LR1 cells as early as 2 days of ATRA treatment. This association was completely abolished by 6 days of treatment. In contrast, in ATRA long-term treatment of NB4-LR1 SFD cells, even though RNA Pol II on hTERT promoter and exon 2 was decreased, a sustained amount remained bound, consistent with the presence of active transcription of hTERT in this cell line despite the continuous presence of ATRA. These results show that downregulation of telomerase activity by ATRA is a consequence of a decrease in transcriptional initiation of the gene. As expected, a strong increase in RNA Pol II association with RARb2 promoter on ATRA treatment was not only observed in ATRA-treated NB4-LR1 cells but also in ATRA-treated NB4-LR1 SFD cells. We investigated by reverse transcriptase PCR RARb2 expression following ATRA treatment of NB4-LR1 and NB4-LR1 SFD cells and showed that in both cell types binding of RNA pol II at RARb2 promoter was associated with a significant increase in the expression of this gene at the RNA level (Supplementary Materials and methods, Supplementary Figure  1S ). This observation shows that the relative incapacity of NB4-LR1 SFD cells to downregulate hTERT during long-term ATRA treatment does not reflect a defect in ATRA signaling. hTERT regulation by retinoids in maturation-resistant APL cells A Azouz et al involved in hTERT regulation through their binding on the proximal core promoter of the hTERT gene. 16, 32, 44, 45 We therefore examined the kinetic of expression and in vivo interaction of these factors with hTERT promoter after ATRA long-term treatment. As shown in Figure 3a and Supplementary Figure 2Sa , the level of c-Myc protein decreased rapidly in ATRA-treated NB4-LR1 cells and was barely detectable after 7 days of ATRA treatment. It is interesting to note that even though it has already been shown that ATRA-induced differentiation is associated with c-Myc downregulation, [33] [34] [35] in our case the decrease occurred independently of differentiation. In contrast, c-Myc remained expressed in NB4-LR1 SFD cells even after 9 days of exposure to ATRA. It can be noted that the expression of Mad-1 slightly decreased in NB4-LR1 cells, whereas Sp1 and CTCF protein levels remained unchanged during ATRA treatment in both NB4-LR1 and NB4-LR1 SFD cells. The interaction of these factors with hTERT promoter was then investigated using ChIP assay on untreated and long-term ATRAtreated cells (Figure 3b and Supplementary Figure 2Sb) . After ATRA treatment of NB4-LR1 cells, c-Myc and Sp1 binding to hTERT promoter was gradually decreased. The reduction in c-Myc binding seems to correlate well with the level of expression of c-Myc protein. Basal fixation of Mad-1 was weak and increased after ATRA treatment by day 2. These data demonstrate, as previously reported during differentiation of leukemic cells, 32 a switch in binding at hTERT promoter from c-Myc to Mad-1 during ATRA long-term treatment of the maturationresistant NB4-LR1 cells. In contrast, in NB4-R1 SFD cells, c-Myc and Sp1 remained bound on hTERT promoter and this binding even increased after 7 days of exposure to ATRA, whereas no modification in the binding of Mad-1 and CTCF was observed.
The decrease in c-Myc protein level in NB4-LR1 cells cannot only be explained by a transcriptional regulation, as c-Myc mRNA level stabilized at about 50% compared with untreated cells even after 15 days of continuous ATRA treatment (data not shown). Therefore, we tested whether this reduction was due to enhanced proteasomal degradation using the proteasome inhibitor MG-132. NB4-LR1 cells were first treated for 10 days with ATRA (1 mM) and then with MG-132 (2.5 mM) for an additional 6 h. Cellular extracts were isolated and western blot analysis for c-Myc, Sp1 and Mad-1 expression was performed. Wilms' tumor-suppressor protein (WT1) has been identified as a repressor of the hTERT promoter, using an expression cloning approach. 21 A potential binding site for this transcription factor is located downstream of the core promoter of hTERT. In hematopoietic cells, WT1 behave as a tumor suppressor, promoting differentiation. However, it has been suggested that it can also act as an oncogene in leukemic cells. 46 Its expression has been shown to be downregulated during ATRA-induced differentiation in both HL-60 and NB4 cells. 47, 48 Expression and in vivo binding of this factor to the hTERT promoter were therefore analyzed as above. Surprisingly, the constitutive WT1 expression was significantly higher in NB4-LR1 SFD than in NB4-LR1 cells. However, the protein level decreased significantly in ATRA-treated cells by day 7. This decrease was also observed in Figure 2 RNA Pol II occupancy of hTERT promoter and exon 2 during ATRA long-term treatment of NB4-LR1 and NB4-LR1 SFD cells. ChIP assays were quantified by real-time PCR using input, IP and No Ab DNA samples. Results are expressed as the relative level over control cells after correcting for differences in the amount of starting (input) chromatin materials. As a specific positive control, we performed PCR analyses using primers specific to a region encompassing RARb2 RARE.
hTERT regulation by retinoids in maturation-resistant APL cells A Azouz et al ATRA-treated NB4-LR1 cells but to a lesser extent. It is interesting to note that in contrast to already published studies, 47, 48 this decrease was observed in the absence of differentiation. Nevertheless, despite a high level of expression WT1 protein in NB4-LR1 SFD cells, its binding to the hTERT promoter was extremely weak. In contrast, in NB4-LR1 cells, even though the WT1 protein level was low, its constitutive binding to the hTERT promoter is higher than in NB4-LR1 SFD and further increased after ATRA treatment. This result suggests a potential role for WT1 in the repression of hTERT by ATRA long-term treatment in the NB4-LR1 cells. The reason why the WT1 repressor does not bind to the hTERT promoter in NB4-LR1 SFD cells is not elucidated and requires further investigation, in keeping with the unrepressed hTERT in these cells (see below).
Histone acetylation is decreased in NB4-LR1 but not in NB4-LR1 SFD cells during ATRA long-term treatment
It has previously been shown that decreased histone acetylation within the hTERT promoter negatively influences hTERT transcription during retinoid-induced differentiation of HL-60. 34, 49 To assess the role of histone modification in the maturation independent pathway of hTERT repression, we performed ChIP assays to examine the patterns of H3 and H4 acetylation. As shown in Figure 4 , in the ATRA-induced maturation-resistant NB4-LR1 cells, a substantial deacetylation of histone H4 and H3 in both the proximal and distal domains of hTERT promoter appeared by days 4 or 2 of ATRA treatment, respectively. This kinetics of deacetylation is in agreement with the decrease in RNA Pol II binding to the proximal promoter and transcribed region and hTERT repression in these cells (Figures 1  and 2 ). In contrast, no significant reduction of H3 and H4 acetylation was observed in the proximal domain of hTERT promoter after ATRA treatment of the NB4-LR1 SFD cells (Figure 4) . Furthermore, even though a deacetylation of these histones in the distal domain of the promoter was observed, it was delayed and by day 6 a sustained amount of acetylated histones remained. PCR analyses using primers specific to the region encompassing RARb2 RARE showed an increase in both H3 and H4 acetylation in agreement with the increased binding of RNA Pol II at RARb2 promoter ( Figure 2 ) and the re-expression of this gene at the RNA level ( Supplementary  Materials and methods, Supplementary Figure 1S ). These data SFD cells. PCR was performed using specific primers as described in Materials and methods and Supplementary Table S1. No amplification was seen when no antibody or IgG serum was used for precipitation or when primers spanning a region from exon 2 (hTERT ChIP-d) of hTERT gene lacking binding sites for the transcription factors analyzed were used for PCR (data not shown). (c) Proteasome inhibitor MG-132 restored c-Myc expression but not its recruitment to hTERT promoter. NB4-LR1 cells were treated with ATRA (1 mM) for 10 days then MG-132 (2.5 mM) was added for an additional 6 h period. Western blot and ChIP analysis were then performed.
hTERT regulation by retinoids in maturation-resistant APL cells A Azouz et al support the conclusion that chromatin changes under ATRA treatment create a promoter context for negative regulation of hTERT transcription in NB4-LR1 cells (decreased histone acetylation), whereas in NB4-LR1 SFD cells, ATRA fails to induce such changes and by maintaining relatively high levels of histone acetylation favors hTERT transcription.
Methylation of CpGs at the distal region of hTERT promoter distinguishes NB4-LR1 and NB4-LR1 SFD cells
That retinoids failed to sufficiently downregulate hTERT in NB4-LR1 SFD cells could well be a consequence of genomic changes at the hTERT gene promoter. These changes could consist of either mutations in the regulatory sequences of the promoter and/or differential DNA methylation of discrete regions in the hTERT promoter of sensitive and resistant cells. DNA sequencing of the hTERT promoter region spanning between nts À650 and þ 150 did not reveal any mutation in any of the two alleles (data not shown). Therefore, the hypothesis of promoter functional invalidation by point mutation and/or deletion to explain decreased hTERT mRNA level is excluded.
As the high GC content of hTERT promoter region suggests a possible role of methylation in the regulation of hTERT gene expression, we analyzed the DNA methylation status of the hTERT promoter in both NB4-LR1 and NB4-LR1 SFD cells, and the impact of ATRA treatment on this status. We monitored the methylation status of the 97 methylable cytosines within a region À650 to þ 150 of the hTERT promoter, using MSP (Methylation specific PCR, Supplementary Materials and methods, Supplementary Figure 3S ) and bisulfite sequencing of cloned Figure 4 ChIP analysis of histone H3 and H4 acetylation in NB4-LR1 and NB4-LR1 SFD ATRA-treated cells. ChIP assays were quantified by realtime PCR. Both the proximal and the distal domains of hTERT promoter were investigated. Results are expressed as the relative level over control cells after correcting for differences in the amount of starting (input) chromatin materials. As a specific positive control, we performed PCR analyses using primers specific to a region encompassing RARb2 RARE.
hTERT regulation by retinoids in maturation-resistant APL cells A Azouz et al alleles ( Figure 5 ). Our results show that both NB4-LR1 and NB4-LR1 SFD cell lines presented a low level of cytosine methylation and their basal total methylation index differed only slightly (7 and 13%, respectively). From the methylation pattern, the hTERT promoter can be dissected into two distinct regions. An upstream region from À650 to approximately À200 from the transcription start sites (CpGs 1-50) and a downstream region from À200 to þ 150 (CpGs 51-97) encompassing the transcription start site and the beginning of exon 1. It can be noted that this region contains most of the transcription factor binding sites. A similar limit between partially methylated and unmethylated regions has previously been described, 31 suggesting that the region surrounding the transcription start site remains unmethylated for hTERT to be expressed. NB4-LR1 cells and NB4-LR1 SFD showed a similar hypomethylation of this proximal promoter region and ATRA treatment did not change this status. This strongly supports the conclusion that DNA methylation of this region does not contribute to the repression of hTERT by ATRA. Interestingly, the upstream promoter region (nt -650 to -200; CpGs 1-50) showed a contrasting picture. Although there were only few methylated sites in the nt À600 to À200 region in untreated NB4-LR1 cells, NB4-LR1 SFD untreated cells showed significantly higher DNA methylation (10 and 30% CpG methylation in NB4-LR1 and NB4-LR1 SFD cells, respectively). Furthermore, in NB4-LR1 cells, ATRA induced a 90% hTERT repression after 7 days of ATRA treatment with no significant change in DNA methylation. By contrast, in NB4-LR1 SFD cells, in which ATRA failed to downregulate hTERT, ATRA treatment induced a strong hypermethylation (65 %) of this region after 7 days of treatment.
Ideally one would like to determine whether inhibition of DNA methylation in this distal domain of hTERT promoter could restore ATRA-induced hTERT repression in NB4-LR1 SFD cells. Unfortunately, the NB4-LR1 SFD subclone, isolated under the selective pressure of ATRA proved to be resistant to 5-azadeoxycytidine-induced demethylation (data not shown).
Resistance to this drug is not unusual and has already been described. 50 However, the two salient differences with the parental NB4-LR1 cells, which downregulated hTERT, are the hypomethylation of this distal domain and the binding of the hTERT repressor, WT1. It can therefore be speculated that this methylation inhibits the binding of WT1 in this cell line and contribute to the lock of the hTERT promoter in its 'on' status.
Discussion
Altogether, our results show that although distinct patterns of transcription factor expression, histone modifications and transcription factor binding at the proximal domain could concur to modulate hTERT gene expression, they are not sufficient to mediate the switch off/on of hTERT expression by retinoids in NB4-LR1 and NB4-LR1 SFD cells. Moreover, this study clearly provides evidence for inversed DNA methylation patterns of the hTERT promoter in its distal domain in the two cell lines, differentially modified by retinoids. Altogether, these results identify two distinct functional domains in the hTERT promoter, a distal region (nts À600 to À200) where hTERT repressor signaling likely converges and a more proximal domain (nts À200 to þ 150) that encodes response elements or binding sites essentially for activators of hTERT expression.
CTCF has been shown to bind to unmethylated genomic domains, including the 5 0 proximal region of hTERT in telomerase-negative cells. 16, 17 Thus, it was not surprising to observe constitutive binding of CTCF to this proximal region in the cells used in this study, as this region is unmethylated in both NB4-LR1 and NB4-LR1 SFD variants. However, through this hTERT regulation by retinoids in maturation-resistant APL cells A Azouz et al binding, CTCF has been described as a repressor of hTERT. Although our results do not exclude that CTCF functions as a repressor, its action is obviously not sufficient alone to repress hTERT expression in NB4-LR1 SFD cells. The results we report in this paper are important because they indicate that DNA methylation might have a key role in hTERT expression, but in a way opposite to what has been proposed so far. When, as exemplified in NB4-LR1 cells, hTERT is hypomethylated, WT1 or a yet nonidentified ATRA-inducible hTERT repressor can bind the promoter and block the transcriptional machinery, even if appropriate transcription factors act downstream on the promoter. On the other hand, DNA methylation of this distal domain could prevent the binding of WT1 or any other potential repressor and therefore allows the promoter to remain activated by appropriate transcription factors such as c-Myc and Sp1. Accordingly, a sustained expression of hTERT in a cell that expresses a hTERT repressor would depend on the following two conditions: first, the expression of transcription factors such as c-Myc and Sp1; and second, a stable DNA methylation of the distal region of the hTERT promoter. NB4-LR1 SFD cells exquisitely fulfill these two conditions. A proposed model for differentiation-independent hTERT regulation in response to ATRA is illustrated in Figure 6 . This model is indeed supported by recent results demonstrating the critical role of endogenous chromatin environment of hTERT gene and its cooperation with repressors recruited to its promoter to reduce basal transcription during cell differentiation. [22] [23] [24] Such a mechanism of de-repression as a result of epigenetic regulation by DNA methylation has recently been shown for survivin. 51 In this study, methylation of survivin promoter inhibits the binding of p53, a repressor of its expression. In keeping, earlier studies showed that methylation of the hTERT promoter at the CTCF-binding site inhibited the binding of CTCF, thus derepressing hTERT in some human tumors. 16, 17 Previous reports showed that a region between À578 and À300 bp upstream of the ATG initiation codon in the hTERT promoter, which corresponds to the domain identified in our study, 20, 52 functions as a transcriptional silencer. This region includes MZF-2 and WT1 binding sites. We were only able to investigate the involvement of WT1 because no available antibodies against MZF-2 exist. Despite a high level of WT1 protein in NB4-LR1 SFD cells, its binding to the hTERT promoter remained weakly detectable compared with the parental NB4-LR1 cells in which WT1 binding was increased on ATRA treatment. The WT1 recognition sequence contains three methylable cytosines, which led us to feel that methylation in this region could have a role on its binding to the hTERT promoter. Yet, it cannot be excluded that this distal region could be targeted by other known or unknown regulatory factors, induced or not by ATRA, whose binding would be methylation dependent.
In conclusion, these findings support the hypothesis that epigenetic modifications of the distal domain of the hTERT promoter accounts for the capacity of retinoid to repress hTERT, the reactivated expression of telomerase in these leukemia cells and a likely mechanism for the ATRA resistance to hTERT downregulation. hTERT regulation by retinoids in maturation-resistant APL cells A Azouz et al (E S-B), Cent pour Sang la Vie and Capucine (E S-B), the Société Française du Cancer, the Société Française d'Hématologie (IT) and Aleppo Pharmaceutical Industries (Alpha), Aleppo, Syria (AA). We thank Dr Sophie Bombard (UMR CNRS 8601) for her comments on the paper and Dr Michèle Goodhardt (INSERM U662) for her critical discussions and English editing of the paper.
